Intravitreal Bevacizumab for Choroidal Neovacularization in Ocular Hitoplamoi Original Reearch Article

Purpoe To define the role of intravitreal bevacizumab in individual with choroidal neovacularization (CNV) reulting from Ocular Hitoplamoi yndrome (OH). Deign Retropective chart review of a urgical therapy. Method We reviewed the coure of 28 eye of 28 patient who underwent intravitreal injection of bevacizumab for treatment of CNV econdary to OH. Outcome wa meaured by pretreatment and pottreatment viual acuity (VA). Reult The average pretreatment logarithm of the minimum angle of reolution (logMAR) VA wa 0.65 (nellen equivalent of 20/88). Mean follow-up wa 22.43 week with an average of 1.8 intravitreal injection. Average final logMAR VA wa 0.43 (nellen equivalent of 20/54). Twenty eye (71%) experienced an increae in central VA, wherea four eye (14%) were unchanged and four eye (14%) experienced a decreae in viion. Concluion Intravitreal bevacizumab may improve or tabilize VA in a ignificant majority of patient with neovacular complication of OH (24 eye [85.7%] in our tudy population).